CSL Plasma A.I CyberSecurity Scoring
04/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for CSL Plasma in 2026.
No incidents recorded for CSL Plasma in 2026.
No incidents recorded for CSL Plasma in 2026.
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals
Latest updates, reports, and threat intel affecting the global network.
A global plasma collection company violated Illinois' genetic privacy law by asking job applicants for their family medical histories in...
Exchange traded funds (ETFs) have become one of the simplest and most effective ways for investors to put money to work in the share market.
Is CSL Ltd (ASX: CSL) stock cheap, expensive, or fairly valued? Let's dig deeper and find out what analysts think about this biotech giant.
CSL Plasma Inc. has agreed to pay $9.9 million to put to rest allegations that the company violated Illinois' Biometric Information Privacy...
Kenia Rincon, CSL Behring's Chief Information Security Officer, recently led a conversation on colorism for the Healthcare Businesswomen's...
A flaw was found in DPDK lib/vhost. Missing length validation before reading command_data in the virtio-net control-queue handler can cause an out-of-bounds read and a host process crash.
Maravel, a PHP framework oriented towards dependency injection, prior to version 10.74.0 has a high-severity Token Replay Vulnerability arising from a structural lifecycle mismatch between stateless token validation engines and high-performance relational caching layers. Any application with low cache memory that causes premature eviction to free up memory and applications running macropay-solutions/maravel-framework that utilize tymon/jwt-auth for API token authentication and blacklist management or any other package that does the same may be affected. This architectural risk might also impact native Laravel applications utilizing cache tags under specific volatile or eviction-capped environments. tymon/jwt-auth automatically probes for cache tag support. If found, it forcefully wraps 14-day token blacklist entries (jti) inside a relational tymon.jwt tag. In environments where the O(1) Atomic Lazy Eviction model is active — either natively inside Maravel-Framework v20.x or manually backported into v10.x via the explicit DI container singletons provided in PR #104 (App\Cache\TaggedCache and App\Cache\TagSet) — a strict global tracking ceiling (Container::TAGGED_CACHE_TTL_CAP_SECONDS) of 7,200 seconds (2 hours) is enforced to secure the system against memory index bloat. This ceiling forcefully truncates the 14-day blacklist lifespan down to a maximum of 2 hours, after which individual tracking keys naturally expire and disappear from the active cache window. Furthermore, because the optimized engine implements a generational version matrix to achieve O(1) flush speeds, any programmatic or manual invocation of a tag flush or reset (e.g., Cache::tags([...])->flush()) instantly bumps the internal atomic master version pointer. This shifts the computed cryptographic composite hash (sha1($this->tags->getNamespace())) for all overlapping components, rendering the entire existing index immediately unreachable. Consequently, through either natural 2-hour expiration or an intervening tag flush execution (like the cache naturally cleaning old values to free up memory), the invalidation state records are entirely wiped out. Because the tokens' physical cryptographic signatures remain structurally valid for up to 14 days, stolen, hijacked, or legitimately logged-out tokens are instantly and silently resurrected across the entire API gateway, leaving the application critically vulnerable to widespread Token Replay Attacks. Because this issue is caused by an upstream architectural assumption within the tymon/jwt-auth package rather than a core defect inside the framework, there is no direct framework version upgrade that can safely bypass this lifecycle collision without breaking business cache recycling bounds. Maravel version 10.74.0 introduced a way to backport the new fixed tagged cache from 20.x into 10.x by resolving TagSet and TaggedCache from DI, which is how this latent architectural lifecycle vulnerability was discovered. Users must apply the decoupled configuration workaround outlined below. As a workaround, make sure that cache memory size does not generate early natural evictions from cache to free up space, deleting blacklisted jwt ids before they expire. Applications must decouple flat authentication vectors from the relational tagging subsystem. This forces token identifiers to write directly to the primary cache keyspace as flat, un-tagged key-value pairs where they securely retain their unclipped 14-day lifecycle.
Sylius is an Open Source eCommerce Framework on Symfony. Starting in version 2.0.0 and prior to version 2.0.18, 2.1.15, and 2.2.6, the `GET /api/v2/shop/payment-requests/{hash}` and `PUT /api/v2/shop/payment-requests/{hash}` endpoints look up the payment request solely by the hash from the URL. No ownership check is performed against the authenticated customer or the underlying order. An attacker who obtains a payment request hash can read the payment request and, through the `payment` IRI in the response, recover the underlying order's `tokenValue` (which itself grants access to the full order, items, addresses, customer email, totals); and/or update the payment request payload (e.g. `target_path`, `after_path`). These fields are used by the front-end controller to redirect the user after the payment, so an attacker can flip them to an attacker-controlled URL and intercept the buyer. The hash is a UUID, so it has to be obtained out-of-band (logs, shared links, referrer headers, a co-located client), but once it is known no other credential is required, neither authentication nor knowledge of the order token. The creation endpoint `POST /api/v2/shop/orders/{tokenValue}/payment-requests` shares the same flaw: it resolves the target order solely from the `tokenValue` in the URL without verifying that the caller owns the order. The issue is fixed in versions 2.0.18, 2.1.15, and 2.2.6. As a workaround, add a query extension that filters the `GET` operation; decorate the `PUT` state provider, guard the `POST` creation endpoint with a command-bus middleware, and wire the services.
Sylius is an Open Source eCommerce Framework on Symfony. Starting in version 2.0.0 and prior to version 2.0.18, 2.1.15, and 2.2.6, an authorization bypass vulnerability exists in the shop account API. The `PATCH /api/v2/shop/account/orders/{tokenValue}/payments/{paymentId}` endpoint, used by an authenticated shop customer to change the payment method of an order that has been placed but not yet paid (state `STATE_NEW`), does not validate that the chosen payment method is enabled for the order's channel. The equivalent checkout endpoint (`PATCH /api/v2/shop/orders/{tokenValue}/payments/{paymentId}`) correctly rejects out-of-channel payment methods with `HTTP 422`; the account endpoint silently accepts them and returns `HTTP 200`. An authenticated customer can therefore assign any globally enabled payment method to their own placed order, including methods that the store operator has explicitly excluded from that channel. The issue is fixed in versions: 2.0.18, 2.1.15, 2.2.6 and above. As a workaround, decorate the `Sylius\Bundle\ApiBundle\Changer\PaymentMethodChangerInterface` service in the application.
Sylius is an Open Source eCommerce Framework on Symfony. Versions 2.0.0 through 2.0.17, 2.1.0 through 2.1.14, and 2.2.0 through 2.2.5 contain an improper workflow enforcement vulnerability in the cart `FormComponent`. When an order is completed while its cart page remains open, the stale LiveComponent does not detect the order’s changed state and continues to permit cart actions, allowing an authenticated customer to modify or permanently delete an already completed order. Versions 2.0.18, 2.1.15, and 2.2.6 contain a patch. As a workaround, deployments can copy the patched `FormComponent` into the application's `src/` directory and override the `sylius_shop.twig.component.cart.form` service definition to use that class.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.